What is Gilead Sciences's stock-based comp?

Gilead Sciences (GILD) reported stock-based comp of $218M in Q1 2026.

How has Gilead Sciences's stock-based comp changed year-over-year?

Gilead Sciences's stock-based comp increased by 4.3% year-over-year, from $209M to $218M.

What is the long-term trend for Gilead Sciences's stock-based comp?

Over 4 years (2021 to 2025), Gilead Sciences's stock-based comp has grown at a 8.9% compound annual growth rate (CAGR), from $635M to $894M.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Gilead Sciences GILD Stock-Based Comp

Stock-Based Comp at other companies

Bristol-Myers SquibbBMY

$146M+1.4%

IncyteINCY

$64.13M+5.2%

ImmunityBio, Inc.IBRX

$8.17M-14.3%

PrecigenPGEN

$3.01M+12.3%

AnaptysBio, Inc.ANAB

$14.22M+55.0%

Iovance Biotherapeutics, Inc.IOVA

$11.27M-50.8%

Other financials

Income statement

See full

Revenue$7.0B+4.4%

Gross profit$5.5B+7.6%

Operating income$2.6B+15.6%

Net income$2.0B+53.7%

EPS (diluted)$1.61+54.8%

Balance sheet

See full

Cash & equivalents$7.6B-3.8%

Total debt$22.2B-11.1%

Total equity$23.5B+22.7%

Total assets$56.3B-0.3%

Cash flow

See full

Operating cash flow$2.5B+44.8%

CapEx$117.0M+12.5%

Free cash flow$2.4B+46.8%

Valuation

See full

Market cap$158.77B+19.1%

Enterprise value$173.32B+13.2%

P/E17.2×-3.9×

P/S5.3×+0.7×

Profitability

See full

Gross margin79.4%+1.1pp

Operating margin34.9%+6.3pp

Net margin31%+10.2pp

FCF margin34.4%+0.1pp

Returns & leverage

See full

Return on equity43.2%+10.7pp

Debt / equity0.9×-0.4×

Current ratio2×+0.6×

Where this comes from

Reported directly by Gilead Sciences in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gilead Sciences's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Gilead Sciences's stock-based comp?: Gilead Sciences (GILD) reported stock-based comp of $218M in Q1 2026.
How has Gilead Sciences's stock-based comp changed year-over-year?: Gilead Sciences's stock-based comp increased by 4.3% year-over-year, from $209M to $218M.
What is the long-term trend for Gilead Sciences's stock-based comp?: Over 4 years (2021 to 2025), Gilead Sciences's stock-based comp has grown at a 8.9% compound annual growth rate (CAGR), from $635M to $894M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.